Saroglitazar | CAS#495399-09-2

MedKoo Cat#: 319702 | Name: Saroglitazar

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Saroglitazar is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India. Saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). Saroglitazar is novel first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action at PPARα lowers high blood triglycerides, and agonist action on PPARγ improves insulin resistance and consequently lowers blood sugar.

Chemical Structure

Saroglitazar

CAS#495399-09-2 (free acid)

Theoretical Analysis

MedKoo Cat#: 319702

Name: Saroglitazar

CAS#: 495399-09-2 (free acid)

Chemical Formula: C25H29NO4S

Exact Mass: 439.1817

Molecular Weight: 439.57

Elemental Analysis: C, 68.31; H, 6.65; N, 3.19; O, 14.56; S, 7.29

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

495399-09-2 (free acid) 1639792-20-3 (magnesium)

Synonym

ZYH1; ZYH-1; ZYH 1; Saroglitazar, trade name: Lipaglyn.

IUPAC/Chemical Name

(S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid

InChi Key

MRWFZSLZNUJVQW-DEOSSOPVSA-N

InChi Code

InChI=1S/C25H29NO4S/c1-4-29-24(25(27)28)17-19-6-10-21(11-7-19)30-16-15-26-18(2)5-14-23(26)20-8-12-22(31-3)13-9-20/h5-14,24H,4,15-17H2,1-3H3,(H,27,28)/t24-/m0/s1

SMILES Code

O=C(O)[C@@H](OCC)CC1=CC=C(OCCN2C(C)=CC=C2C3=CC=C(SC)C=C3)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 439.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Vuppalanchi R, Cruz MM, Momin T, Shaikh F, Swint K, Patel H, Parmar D. Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment. Clin Pharmacol Ther. 2024 Oct 2. doi: 10.1002/cpt.3450. Epub ahead of print. PMID: 39355940. 2: Jakkamsetti MS, Kolusu AS, Rongala S, Arakareddy BP, Nori LP, Samudrala PK. Saroglitazar, a PPAR α/γ agonist alleviates 3-Nitropropionic acid induced neurotoxicity in rats: Unveiling the underlying mechanisms. Neurotoxicology. 2024 Sep 24;105:131-146. doi: 10.1016/j.neuro.2024.09.004. Epub ahead of print. PMID: 39326639. 3: Engin A. Protein Kinases in Obesity, and the Kinase-Targeted Therapy. Adv Exp Med Biol. 2024;1460:199-229. doi: 10.1007/978-3-031-63657-8_7. PMID: 39287853. 4: Hu Y, Sun C, Chen Y, Liu YD, Fan JG. Pipeline of New Drug Treatment for Non- alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease. J Clin Transl Hepatol. 2024 Sep 28;12(9):802-814. doi: 10.14218/JCTH.2024.00123. Epub 2024 Jul 31. PMID: 39280073; PMCID: PMC11393841. 5: Mishra SK, Mishra V. Saroglitazar Enhances Memory Functions and Adult Neurogenesis via Up-Regulation of Wnt/β Catenin Signaling in the Rat Model of Dementia. ACS Chem Neurosci. 2024 Oct 2;15(19):3449-3458. doi: 10.1021/acschemneuro.4c00167. Epub 2024 Sep 12. PMID: 39265183. 6: Khaznadar F, Khaznadar O, Petrovic A, Hefer M, Gjoni F, Gjoni S, Steiner J, Smolic M, Bojanic K. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development. Curr Issues Mol Biol. 2024 Jun 21;46(7):6300-6314. doi: 10.3390/cimb46070376. PMID: 39057018; PMCID: PMC11275123. 7: Afarin R, Hatami M, Monjezi S, Bineshfar F, Ahangarpour A. Suppression of TGF-β/Smad3 signaling pathway by Capparis spinosa and quercetin in a rat model of nonalcoholic steatohepatitis. Iran J Basic Med Sci. 2024;27(9):1096-1104. doi: 10.22038/IJBMS.2024.76264.16497. PMID: 39055878; PMCID: PMC11266748. 8: Pramanik S, Pal P, Ray S. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies. World J Methodol. 2024 Jun 20;14(2):91319. doi: 10.5662/wjm.v14.i2.91319. PMID: 38983664; PMCID: PMC11229880. 9: Lin KH, Amigo N, Ortiz P, Alonso C, Smolensky AV, Parmar D, Chalasani NP, Gawrieh S. The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients. Clin Investig Arterioscler. 2024 Jun 29:S0214-9168(24)00041-X. English, Spanish. doi: 10.1016/j.arteri.2024.04.004. Epub ahead of print. PMID: 38945785. 10: Afarin R, Dinarvand N, Azizi Dariuni H, Orak G, Jaberian Asl B, Azizi R, Khedri A. Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling. Iran J Basic Med Sci. 2024;27(8):1015-1022. doi: 10.22038/IJBMS.2024.75293.16320. PMID: 38911240; PMCID: PMC11193507. 11: Tavaglione F, Loomba R. Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH. J Clin Exp Hepatol. 2024 Sep- Oct;14(5):101449. doi: 10.1016/j.jceh.2024.101449. Epub 2024 May 14. PMID: 38881684; PMCID: PMC11170343. 12: Dinarvand N, Afarin R, Shakerian E, Bavarsad SS, Mohammadtaghvaei N. The effect of saraglitazar on TGF-β-induced smad3 phosphorylation and expression of genes related to liver fibrosis in LX2 cell line. Mol Biol Rep. 2024 Apr 20;51(1):541. doi: 10.1007/s11033-024-09443-3. PMID: 38642208. 13: Mir BA, Sharma B, Sharma R, Bodh V, Chauhan A, Majeed T, Haq I, Sharma N, Sharma D. A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL. J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101398. doi: 10.1016/j.jceh.2024.101398. Epub 2024 Mar 18. PMID: 38628977; PMCID: PMC11017282. 14: Ezhilarasan D. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD. Metabolism. 2024 Jun;155:155912. doi: 10.1016/j.metabol.2024.155912. Epub 2024 Apr 11. PMID: 38609038. 15: Kamata S, Honda A, Kashiwagi N, Shimamura A, Yashiro S, Komori Y, Hosoda A, Akahoshi N, Ishii I. Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease. Biomedicines. 2024 Mar 11;12(3):624. doi: 10.3390/biomedicines12030624. PMID: 38540237; PMCID: PMC10967972. 16: Yellurkar ML, Prasanna VS, Das P, Sarkar S, Matta R, Dhaked DK, Peraman R, Taraphdar AK, Nanjappan SK, Velayutham R, Arumugam S. Indigenous wisdom of a Kwatha to treat NASH: An insight into the mechanism. J Ethnopharmacol. 2024 May 23;326:117935. doi: 10.1016/j.jep.2024.117935. Epub 2024 Feb 24. PMID: 38408692. 17: Attia SH, Saadawy SF, El-Mahroky SM, Nageeb MM. Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway. Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):5953-5974. doi: 10.1007/s00210-024-03004-y. Epub 2024 Feb 20. PMID: 38376539; PMCID: PMC11329427. 18: Lin W, Wang JX, Liu YJ. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis. Syst Rev. 2024 Jan 29;13(1):46. doi: 10.1186/s13643-024-02460-0. PMID: 38287391; PMCID: PMC10823686. 19: Afarin R, Dinarvand N, Jaberian Asl B, Orak G, Shakerian E, Bineshfar F, Ahangarpour A. Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats. Iran J Basic Med Sci. 2024;27(2):241-246. doi: 10.22038/IJBMS.2023.70157.15255. PMID: 38234671; PMCID: PMC10790293. 20: International BR. Retracted: Antidiabetic Effect of Tamarindus indica and Momordica charantia and Downregulation of TET-1 Gene Expression by Saroglitazar in Glucose Feed Adipocytes and Their Involvement in the Type 2 Diabetes-Associated Inflammation In Vitro. Biomed Res Int. 2024 Jan 9;2024:9843135. doi: 10.1155/2024/9843135. PMID: 38230201; PMCID: PMC10791225.

View History

Azido-PEG10-CH2CO2-NHS

MedKoo CAT#: 123591

CAS#: N/A